Lesinurad Combined With Allopurinol: A Randomized, Double‐Blind, Placebo‐Controlled Study in Gout Patients With an Inadequate Response to Standard‐of‐Care Allopurinol (a US‐Based Study)-Reference-Cited by-同舟云学术

Lesinurad Combined With Allopurinol: A Randomized, Double‐Blind, Placebo‐Controlled Study in Gout Patients With an Inadequate Response to Standard‐of‐Care Allopurinol (a US‐Based Study)

Published:2016-12-28 Issue:1 Volume:69 Page:203-212
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Saag Kenneth G.¹,Fitz‐Patrick David²,Kopicko Jeff³,Fung Maple³,Bhakta Nihar³,Adler Scott⁴,Storgard Chris³,Baumgartner Scott³,Becker Michael A.⁵

Affiliation:

1. University of Alabama at Birmingham

2. East‐West Medical Research InstituteHonolulu Hawaii

3. Ardea BiosciencesSan Diego California

4. AstraZeneca Pharmaceuticals, Gaithersburg, Maryland

5. University of ChicagoChicago Illinois

Funder

Ardea Biosciences, a member of the AstraZeneca group

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.39840

Reference33 articles.

1. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

2. Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol

3. Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout

4. An open-label, 6-month study of allopurinol safety in gout: The LASSO study

5. Febuxostat: a new treatment for hyperuricaemia in gout

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. History of Treatments Used to Treat Gout and Hyperuricemia;Biosciences Biotechnology Research Asia;2023-12-31

2. Pipeline Therapies for Gout;Current Rheumatology Reports;2023-12-22

3. Arthroscopic surgery for ankle gouty arthritis: a retrospective analysis of clinical outcomes at six month follow-up based on a novel classification system;International Orthopaedics;2023-12-15

4. Systematic review and model-based analysis to identify whether renal safety risks of URAT1 inhibitors are fully determined by uric acid-lowering efficacies;Seminars in Arthritis and Rheumatism;2023-12

5. Urate‐Lowering Drugs and Muscle Injury: A Systematic Review and Network Meta‐Analysis;The Journal of Clinical Pharmacology;2023-10-30